Abstracts tagged "clinical trials and ulcers"

Abstract Number: 1791 • 2018 ACR/ARHP Annual Meeting
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome in a Phase III Study: A Prespecified Analysis By Baseline Patient Demographics and Disease Characteristics
Gulen Hatemi¹, Alfred Mahr², Mitsuhiro Takeno³, Do-Young Kim⁴, Melike Melikoglu¹, Sue Cheng⁵, Shannon McCue⁵, Maria Paris⁵, Mindy Chen⁵ and Yusuf Yazici⁶, ¹Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ²Hospital Saint-Louis, University Paris Diderot, Paris, France, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴Yonsei University College of Medicine and Severance Hospital, Seoul, Korea, Republic of (South), ⁵Celgene Corporation, Summit, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU) that can be disabling and negatively affect quality of life.…
Abstract Number: 2789 • 2018 ACR/ARHP Annual Meeting
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 28 Weeks: Results from a Phase III Study
Gulen Hatemi¹, Alfred Mahr², Yoshiaki Ishigatsubo³, Yeong Wook Song⁴, Melike Melikoglu⁵, Sue Cheng⁶, Shannon McCue⁶, Maria Paris⁶, Mindy Chen⁶ and Yusuf Yazici⁷, ¹Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey, ²Hospital Saint-Louis, University Paris Diderot, Paris, France, ³Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁴Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁵Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ⁶Celgene Corporation, Summit, NJ, ⁷New York University School of Medicine, New York, NY
Background/Purpose: Behçet’s syndrome is a chronic, relapsing, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU), which can be disabling and substantially impact quality of…
Abstract Number: 2841 • 2018 ACR/ARHP Annual Meeting
Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup
Mitsuhiro Takeno¹, Yoshiya Tanaka², Hajime Kono³, Shouji Sugii⁴, Mitsumasa Kishimoto⁵, Sue Cheng⁶, Shannon McCue⁶, Maria Paris⁶ and Hiroaki Dobashi⁷, ¹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁴Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁵Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁶Celgene Corporation, Summit, NJ, ⁷Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in a global, phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with Behçet’s syndrome and…
Abstract Number: 2756 • 2014 ACR/ARHP Annual Meeting
Treatment of Mucocutaneous Manifestations in Behçet’s Disease with Anakinra: A Pilot Open-Label Study
Peter C. Grayson¹, Yusuf Yazici², Elaine Novakovich³, Elizabeth Joyal⁴, Raphaela T. Goldbach-Mansky⁴ and Cailin H. Sibley^3,5, ¹NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³National Institutes of Health Clinical Center, Bethesda, MD, ⁴NIAMS, National Institutes of Health Clinical Center, Bethesda, MD, ⁵Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: IL-1 blocking therapy shows promise in the treatment of Behçet’s eye disease, but its effect on mucocutaneous manifestations is unknown. Methods: 6 patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].